221 related articles for article (PubMed ID: 11683696)
1. Long-term lansoprazole treatment for gastro-oesophageal reflux disease: clinical efficacy and influence on gastric mucosa.
Geboes K; Dekker W; Mulder CJ; Nusteling K;
Aliment Pharmacol Ther; 2001 Nov; 15(11):1819-26. PubMed ID: 11683696
[TBL] [Abstract][Full Text] [Related]
2. Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during 12 months of treatment with omeprazole and lansoprazole in patients with gastro-oesophageal reflux disease.
Stolte M; Meining A; Schmitz JM; Alexandridis T; Seifert E
Aliment Pharmacol Ther; 1998 Mar; 12(3):247-53. PubMed ID: 9570259
[TBL] [Abstract][Full Text] [Related]
3. Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial.
Kuipers EJ; Nelis GF; Klinkenberg-Knol EC; Snel P; Goldfain D; Kolkman JJ; Festen HP; Dent J; Zeitoun P; Havu N; Lamm M; Walan A
Gut; 2004 Jan; 53(1):12-20. PubMed ID: 14684569
[TBL] [Abstract][Full Text] [Related]
4. Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during long-term acid-suppressive treatment in Japan.
Uemura N; Okamoto S; Yamamoto S; Matsumura N; Yamaguchi S; Mashiba H; Sasaki N; Taniyama K
Aliment Pharmacol Ther; 2000 Oct; 14(10):1345-52. PubMed ID: 11012481
[TBL] [Abstract][Full Text] [Related]
5. Helicobacter pylori gastritis and epithelial cell proliferation in patients with reflux oesophagitis after treatment with lansoprazole.
Berstad AE; Hatlebakk JG; Maartmann-Moe H; Berstad A; Brandtzaeg P
Gut; 1997 Dec; 41(6):740-7. PubMed ID: 9462205
[TBL] [Abstract][Full Text] [Related]
6. Treatment with a proton pump inhibitor promotes corpus gastritis in patients with Helicobacter pylori-infected antrum-predominant gastritis.
Suzuki M; Suzuki H; Kitahora T; Miyazawa M; Nagahashi S; Suzuki K; Ishii H
Aliment Pharmacol Ther; 2002 Jan; 16(1):159-65. PubMed ID: 11856091
[TBL] [Abstract][Full Text] [Related]
7. Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia.
Eissele R; Brunner G; Simon B; Solcia E; Arnold R
Gastroenterology; 1997 Mar; 112(3):707-17. PubMed ID: 9041231
[TBL] [Abstract][Full Text] [Related]
8. Factors influencing Helicobacter pylori eradication with 2 week combination therapy of lansoprazole and amoxycillin: intragastric distribution of colonization and gastric mucosal atrophy.
Saita H; Murakami M; Takahashi Y; Sou Y; Kaitani K; Nishio K; Kita T
J Gastroenterol Hepatol; 1998 Jul; 13(7):725-31. PubMed ID: 9715425
[TBL] [Abstract][Full Text] [Related]
9. Helicobacter pylori effects on gastritis, gastrin and enterochromaffin-like cells in Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome acid hypersecretors treated long-term with lansoprazole.
Hirschowitz BI; Haber MM
Aliment Pharmacol Ther; 2001 Jan; 15(1):87-103. PubMed ID: 11136282
[TBL] [Abstract][Full Text] [Related]
10. Effects of 5 years of treatment with rabeprazole or omeprazole on the gastric mucosa.
Rindi G; Fiocca R; Morocutti A; Jacobs A; Miller N; Thjodleifsson B;
Eur J Gastroenterol Hepatol; 2005 May; 17(5):559-66. PubMed ID: 15827447
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the effects of Helicobacter pylori eradication therapy on gastric antral epithelial hyperproliferation: a prospective six-month follow-up study.
Demiray M; Gulten M; Manavoglu O; Evrensel T; Ulukaya E; Yerci O; Kanat O; Kurt E; Arslan M; Gonullu G; Demiray H; Gulten T; Memik F
Hepatogastroenterology; 2004; 51(59):1531-5. PubMed ID: 15362794
[TBL] [Abstract][Full Text] [Related]
12. Chronic inflammation at the gastroesophageal junction (carditis) appears to be a specific finding related to Helicobacter pylori infection and gastroesophageal reflux disease. The Central Finland Endoscopy Study Group.
Voutilainen M; Färkkilä M; Mecklin JP; Juhola M; Sipponen P
Am J Gastroenterol; 1999 Nov; 94(11):3175-80. PubMed ID: 10566710
[TBL] [Abstract][Full Text] [Related]
13. Changing patterns of Helicobacter pylori gastritis in long-standing acid suppression.
Moayyedi P; Wason C; Peacock R; Walan A; Bardhan K; Axon AT; Dixon MF
Helicobacter; 2000 Dec; 5(4):206-14. PubMed ID: 11179985
[TBL] [Abstract][Full Text] [Related]
14. The effect of eradication therapy on histological changes in the gastric mucosa in patients with non-ulcer dyspepsia and Helicobacter pylori infection. Prospective randomized intervention study.
Kyzekova J; Mour J
Hepatogastroenterology; 1999; 46(27):2048-56. PubMed ID: 10430396
[TBL] [Abstract][Full Text] [Related]
15. The effects of short-term lansoprazole therapy on Helicobacter pylori infection and antral gastritis in duodenal ulcer patients.
Jhala NC; McFarland MM; Brightman SA; Morale B; Rubin W; Atkinson BF
Am J Gastroenterol; 1995 Oct; 90(10):1824-8. PubMed ID: 7572902
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of low-dose lansoprazole in the treatment of non-erosive gastrooesophageal reflux disease. Influence of infection by Helicobacter pylori.
Castro Fernández M; García Díaz E; Larraona JL; Rodríguez Hornillo MC; Lamas Rojas E; Núñez Hospital D; Pallarés Querol M
Rev Esp Enferm Dig; 2006 Mar; 98(3):170-9. PubMed ID: 16737416
[TBL] [Abstract][Full Text] [Related]
17. Helicobacter pylori and symptomatic relapse of gastro-oesophageal reflux disease: a randomised controlled trial.
Schwizer W; Thumshirn M; Dent J; Guldenschuh I; Menne D; Cathomas G; Fried M
Lancet; 2001 Jun; 357(9270):1738-42. PubMed ID: 11403809
[TBL] [Abstract][Full Text] [Related]
18. Helicobacter pylori-negative gastritis in erosive esophagitis, nonerosive reflux disease or functional dyspepsia patients.
Peura DA; Haber MM; Hunt B; Atkinson S
J Clin Gastroenterol; 2010 Mar; 44(3):180-5. PubMed ID: 19687753
[TBL] [Abstract][Full Text] [Related]
19. A prospective trial of lansoprazole triple therapy for pediatric Helicobacter pylori infection.
Shashidhar H; Peters J; Lin CH; Rabah R; Thomas R; Tolia V
J Pediatr Gastroenterol Nutr; 2000 Mar; 30(3):276-82. PubMed ID: 10749411
[TBL] [Abstract][Full Text] [Related]
20. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa.
Klinkenberg-Knol EC; Nelis F; Dent J; Snel P; Mitchell B; Prichard P; Lloyd D; Havu N; Frame MH; Romàn J; Walan A;
Gastroenterology; 2000 Apr; 118(4):661-9. PubMed ID: 10734017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
